These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29714519)

  • 1. Sources of Safety Data and Statistical Strategies for Design and Analysis: Clinical Trials.
    Zink RC; Marchenko O; Sanchez-Kam M; Ma H; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):141-158. PubMed ID: 29714519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.
    Marchenko O; Russek-Cohen E; Levenson M; Zink RC; Krukas-Hampel MR; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):170-186. PubMed ID: 29714518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance.
    Izem R; Sanchez-Kam M; Ma H; Zink R; Zhao Y
    Ther Innov Regul Sci; 2018 Mar; 52(2):159-169. PubMed ID: 29714520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction to the Special Section for Sources of Safety Data and Statistical Strategies for Design and Analysis.
    Zink RC
    Ther Innov Regul Sci; 2018 Mar; 52(2):140. PubMed ID: 29714517
    [No Abstract]   [Full Text] [Related]  

  • 5. Sources of Safety Data and Statistical Strategies for Design and Analysis: Transforming Data Into Evidence.
    Ma H; Russek-Cohen E; Izem R; Marchenko OV; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):187-198. PubMed ID: 29714524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team.
    Crowe BJ; Xia HA; Berlin JA; Watson DJ; Shi H; Lin SL; Kuebler J; Schriver RC; Santanello NC; Rochester G; Porter JB; Oster M; Mehrotra DV; Li Z; King EC; Harpur ES; Hall DB
    Clin Trials; 2009 Oct; 6(5):430-40. PubMed ID: 19846894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining, monitoring and combining safety information in clinical trials.
    Enas GG; Goldstein DJ
    Stat Med; 1995 May 15-30; 14(9-10):1099-111; discussion 1113-6. PubMed ID: 7569503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.
    Unkel S; Amiri M; Benda N; Beyersmann J; Knoerzer D; Kupas K; Langer F; Leverkus F; Loos A; Ose C; Proctor T; Schmoor C; Schwenke C; Skipka G; Unnebrink K; Voss F; Friede T
    Pharm Stat; 2019 Mar; 18(2):166-183. PubMed ID: 30458579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing safety signals in large endpoint trials.
    Alemayehu D
    Curr Drug Saf; 2008 May; 3(2):86-90. PubMed ID: 18690986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graphical approaches to the analysis of safety data from clinical trials.
    Amit O; Heiberger RM; Lane PW
    Pharm Stat; 2008; 7(1):20-35. PubMed ID: 17323410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative.
    Calis KA; Archdeacon P; Bain R; DeMets D; Donohue M; Elzarrad MK; Forrest A; McEachern J; Pencina MJ; Perlmutter J; Lewis RJ
    Clin Trials; 2017 Aug; 14(4):342-348. PubMed ID: 28503947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian methods for design and analysis of safety trials.
    Price KL; Xia HA; Lakshminarayanan M; Madigan D; Manner D; Scott J; Stamey JD; Thompson L
    Pharm Stat; 2014; 13(1):13-24. PubMed ID: 23897858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Missing data in confirmatory clinical trials.
    Flyer P; Hirman J
    J Biopharm Stat; 2009 Nov; 19(6):969-79. PubMed ID: 20183459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the limitations of statistical analysis of treatment outcomes used in periodontal research.
    Galgut PN
    J Int Acad Periodontol; 2003 Oct; 5(4):92-7. PubMed ID: 14604057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subgroups: time to go back to basic statistical principles?
    Keene ON; Garrett AD
    J Biopharm Stat; 2014; 24(1):58-71. PubMed ID: 24392978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Data and safety monitoring during randomized controlled trials of nursing interventions.
    Artinian NT; Froelicher ES; Vander Wal JS
    Nurs Res; 2004; 53(6):414-8. PubMed ID: 15586138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?
    Naci H; Ioannidis JP
    Annu Rev Pharmacol Toxicol; 2015; 55():169-89. PubMed ID: 25149917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions.
    Loke YK
    Br J Clin Pharmacol; 2012 Jun; 73(6):908-11. PubMed ID: 22360319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
    Donnelly H; Alemayehu D; Botgros R; Comic-Savic S; Eisenstein B; Lorenz B; Merchant K; Pelfrene E; Reith C; Santiago J; Tiernan R; Wunderink R; Tenaerts P; Knirsch C
    Clin Infect Dis; 2016 Aug; 63 Suppl 2():S39-45. PubMed ID: 27481952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.